Results 141 to 150 of about 3,560 (171)

Thrombopoietin-receptor agonists

Current Opinion in Hematology, 2012
Thrombopoietin-receptor agonists (TPO-RAs) have been approved for use in immune thrombocytopenia (ITP) after showing safety and efficacy. There is increasing interest to expand the role of TPO-RAs, both in ITP as well as in other thrombocytopenic disorders.In ITP, more studies are providing evidence of TPO-RA efficacy and safety, as well as their ...
Paul A, Basciano, James B, Bussel
openaire   +2 more sources

Thrombopoietin Receptor Agonists: A Critical Review

Seminars in Hematology, 2015
Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging ...
William B, Mitchell, James B, Bussel
openaire   +2 more sources

Thrombopoietin-Receptor Agonists for Immune Thrombocytopenia

New England Journal of Medicine, 2011
To the Editor: In response to the review by Imbach and Crowther (Aug. 25 issue)1 of thrombopoietin-receptor agonists for primary immune thrombocytopenia: we would like to draw attention to the fact...
Jansen, Gerard, Swart, RM, te Boekhorst, Peter   +2 more
openaire   +3 more sources

The pharmacology and clinical application of thrombopoietin receptor agonists

International Journal of Hematology, 2014
The discovery and application of thrombopoietin (TPO) and thrombopoietin receptor (TPOR) agonists have changed the clinical treatment of thrombocytopenia. These compounds exert favorable clinical effects without the adverse events caused by traditional treatments (e.g., corticosteroids, immunoglobulins, monoclonal antibodies and splenectomy).
Caizheng, Li, Li, Zheng
openaire   +2 more sources

Eltrombopag: A Novel Oral Thrombopoietin Receptor Agonist

Annals of Pharmacotherapy, 2010
To review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) and thrombocytopenia associated with hepatitis C virus (HCV) cirrhosis.A Cochrane Controlled Trial Register, clinicaltrials.gov, EMBASE, and MEDLINE search was performed ...
Shelby L, Corman, Rima A, Mohammad
openaire   +2 more sources

Thrombopoietin receptor agonists in the treatment of thrombocytopenia

Current Opinion in Hematology, 2009
The basis of treatment for immune thrombocytopenic purpura (ITP) has conventionally relied on nonspecific immune suppression designed to reduce platelet destruction. As a consequence, at least half of the morbidity and mortality in this condition is related to infection secondary to treatment, and alternative treatments are desirable.It has been shown ...
openaire   +2 more sources

New thrombopoietin receptor agonists for platelet disorders

Drugs of Today, 2012
Since thrombopoietin (TPO) was cloned in 1994, TPO receptor (TPO-R) agonists have been developed which have shown significant clinical activity in various conditions characterized by thrombocytopenia. First-generation TPO-R agonists were recombinant forms of human TPO.
S, Homeida, C, Ebdon, P, Batty, B, Jackson, S, Kolade, C, Bateman, Y Y, Peng, R, Stasi   +7 more
openaire   +2 more sources

Thrombopoietin Receptor Agonists

2017
Thrombopoietin receptor agonists (TPO-RAs) should be considered for the treatment of “refractory” autoimmune thrombocytopenia (ITP). In contrast to other medications, TPO-RAs increase platelets via stimulating the production of megakaryocytes/platelets in the bone marrow. This chapter has dealt with the mechanism, efficacy, and safety of TPO-RAs.
openaire   +1 more source

Pyrimidine benzamide-based thrombopoietin receptor agonists

Bioorganic & Medicinal Chemistry Letters, 2007
A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by ...
Lawrence A, Reiter, Chakrapani, Subramanyam, Emilio J, Mangual, Christopher S, Jones, Marc I, Smeets, William H, Brissette, Sandra P, McCurdy, Paul D, Lira, Robert G, Linde, Qifang, Li, Fangning, Zhang, Amy S, Antipas, Laura C, Blumberg, Jonathan L, Doty, James P, Driscoll, Michael J, Munchhof, Sharon L, Ripp, Andrei, Shavnya, Richard M, Shepard, Diana, Sperger, Lisa M, Thomasco, Kristen A, Trevena, Lilli A, Wolf-Gouveia, Liling, Zhang   +23 more
openaire   +2 more sources

Mechanisms and therapeutic prospects of thrombopoietin receptor agonists

Seminars in Hematology, 2019
The second-generation thrombopoietin (TPO) receptor agonists eltrombopag and romiplostim are potent activators of megakaryopoiesis and represent a growing treatment option for patients with thrombocytopenic hematological disorders. Both TPO receptor agonists have been approved worldwide for the treatment of children and adults with chronic immune ...
James Bussel, Austin Kulasekararaj, Nichola Cooper, Amit Verma, Ulrich Steidl, John W. Semple, Britta Will   +6 more
openaire   +2 more sources